Life sciences waiting on social media rules

Share this article:
The life sciences industry is sitting on the sidelines and waiting for regulatory guidance, rather than jumping into wide-scale use of social media, according to a Deloitte Research report.
The report said that part of the hesitation may be because the industry thinks of social networks as marketing, a more-targeted form of DTC advertising. However, it says, social networks are promising as tools that let a company collect information from, communicate to, and collaborate with people outside company walls.
Deloitte said its study described a framework for how social networks are being used today and in the future; explained how social networks add value beyond marketing but across the commercial and research organization; discussed survey data from industry professionals who are using or plan to use social networks; explored the accelerators and barriers to social networking use in the industry; identified when it is appropriate to use a social network and for what purpose; and examined the right governance and policy measures that should be in place.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?